 Evidence antiplatelet aggregation action doxazosin patients hypertension ex vivo study Eighteen patients mean age years study patients diagnosis mild moderate essential hypertension diastolic blood pressure mm Hg study design single blind phases phase placebo weeks phase II active treatment weeks doses doxazosin weeks mg/day Results doxazosin antihypertensive effect dose dependent Systolic diastolic blood pressures effect heart rate Doxazosin platelet aggregation epinephrine adenosine diphosphate collagen dose-dependent manner addition treatment doxazosin total serum cholesterol triglyceride levels standard biochemical parameters doxazosin distinct therapeutic advantage modulation atherogenic thromboembolic factors coronary heart disease